Attached files

file filename
EX-99.1 - EX-99.1 - Talecris Biotherapeutics Holdings Corp.a11-1850_2ex99d1.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 


 

Date of Report (Date of earliest event reported): February 23, 2011

 

TALECRIS BIOTHERAPEUTICS HOLDINGS CORP.

 (Exact name of registrant as specified in its charter)

 

Delaware
(State or other
jurisdiction of incorporation)

 

001-34473
(Commission
File Number)

 

20-2533768
(I.R.S. Employer
Identification No.)

 

 

 

P.O. Box 110526
4101 Research Commons
79 T.W. Alexander Drive

Research Triangle Park, North Carolina

 

 

 

 

27709

(Address of principal executive offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (919) 316-6300

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

o    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 2.02 Results of Operations and Financial Condition.

 

On February 23, 2011, Talecris Biotherapeutics Holdings Corp. issued a press release announcing its financial results for the three and twelve months ended December 31, 2010. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.

 

The information in this report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be incorporated by reference in any registration statement filed under the Securities Act of 1933, as amended, unless specifically identified therein as being incorporated by reference therein.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

No.

 

Description

 

 

 

99.1

 

Press Release dated February 23, 2011

 

2



 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

TALECRIS BIOTHERAPEUTICS

 

HOLDINGS CORP.

 

 

 

 

By:

/s/ John Hanson

 

Name:

John Hanson

 

Title:

Executive Vice President and Chief Financial Officer

 

 

 

 

 

 

Date:       February 23, 2011

 

3



 

EXHIBIT INDEX

 

No.

 

Description

 

 

 

 

 

99.1

 

Press Release dated February 23, 2011

 

 

4